On 10–11 January 2026, the China Respiratory Conference 2026 was held grandly in Beijing. With the theme "Building a Resilient Care System for Infectious Respiratory Diseases", the event brought together 460+ experts and scholars in respiratory medicine and related disciplines, including Wang Chen, Qu Jieming, Song Yuanlin, Dai Huaping, and other leading figures. As an innovative medical approach, Asclepius Meditec was invited to participate, attracting significant attention from researchers and clinicians!
2026 China Respiratory Medicine Development Conference
一、2026中国呼吸学科发展大会隆重开幕
Grand Opening of the China Respiratory Conference 2026
1月10日上午，2026中国呼吸学科发展大会在北京隆重开幕，大会主席、国家呼吸医学中心主任王辰院士发表主旨报告。
On the morning of 10 January, the China Respiratory Conference 2026 commenced in Beijing with an opening address by Academician Wang Chen, Director of the National Respiratory Medicine Centre and Chairman of the conference.
王辰院士发表大会主旨报告
针对大会主题的具体内容，邀请多学科顶级专家以专题报告形式进行阐述，在之后的讨论环节，与会专家们就本次大会主题进一步展开深入研讨。
尤为值得关注的是，出席本次盛会的多位行业学者，均在氢氧医学研究领域深耕多年，不仅参与了多项核心课题研究，更为此领域的创新突破作出了重要贡献。
Regarding the specific content of the conference theme, top experts from various disciplines were invited to present their insights in the form of special reports. In the subsequent discussion session, the participating experts further engaged in in-depth discussions on the conference theme.
Of particular note is that many of the scholars attending this grand event have been deeply involved in hydrogen-oxygen medical research for many years, participating in numerous core research projects and making significant contributions to innovative breakthroughs in this field.
瞿介明教授发表演讲Professor Qu Jieming delivered a speech.
（瞿介明教授是上海交通大学医学院附属瑞金医院党委书记、上海市呼吸传染病应急防控与诊治重点实验室主任、上海交通大学医学院呼吸病研究所所长）Professor Qu Jieming is the Party Secretary of Ruijin Hospital affiliated with Shanghai Jiao Tong University School of Medicine, Director of the Shanghai Key Laboratory of Emergency Prevention, Control and Treatment of Respiratory Infectious Diseases, and Director of the Institute of Respiratory Diseases at Shanghai Jiao Tong University School of Medicine.
上海交通大学医学院附属瑞金医院（中国综合实力前十的公立医院之一）瞿介明教授，他与张文宏教授牵头开展的前瞻性、多中心、随机对照临床试验，评估氢氧气机用于新型冠状病毒肺炎（COVID-19）辅助治疗的有效性和安全性，论文已发表[1]。该项研究结果显示，与单独吸氧相比，吸入氢氧可缩短新冠病毒的转阴时间，降低炎症因子水平，缓解肺部病变，从而减少了早期重症病例的发生。
Professor Qu Jieming from Ruijin Hospital affiliated with Shanghai Jiao Tong University School of Medicine (one of the top ten public hospitals in China in terms of overall strength) led a prospective, multi-center, randomized controlled clinical trial with Professor Zhang Wenhong to evaluate the efficacy and safety of hydrogen-oxygen inhalation therapy as an adjunct treatment for COVID-19. The paper has been published [1]. The results of this study showed that compared to oxygen therapy alone, hydrogen-oxygen inhalation shortened the time to viral clearance, reduced inflammatory cytokine levels, and alleviated lung lesions, thus reducing the occurrence of early severe cases.
宋元林教授发表演讲Professor Song Yuanlin delivered a speech.
（宋元林教授是复旦大学附属中山医院呼吸与危重医学科主任、上海市呼吸病研究所副所长）Professor Song Yuanlin is the Director of the Department of Respiratory and Critical Care Medicine at Zhongshan Hospital affiliated with Fudan University and the Deputy Director of the Shanghai Institute of Respiratory Diseases.
上海复旦大学附属中山医院（中国综合实力前十的公立医院之一）宋元林教授，是氢氧医学应用于慢阻肺的临床研究研究者之一，参与了潓美氢氧气机的适应症研究以及上市后研究。
Professor Song Yuanlin of Zhongshan Hospital affiliated with Fudan University in Shanghai (one of the top ten public hospitals in China in terms of overall strength) is one of the researchers involved in the clinical research of hydrogen-oxygen therapy for chronic obstructive pulmonary disease (COPD). He participated in the research on the indications and post-market studies of the Asclepius Meditec hydrogen-oxygen therapy machine.
代华平教授发表演讲Professor Dai Huaping delivered a speech.
（代华平教授是国家呼吸医学中心副主任、中日友好医院呼吸与危重症医学科三部主任）Professor Dai Huaping is the Deputy Director of the National Respiratory Medicine Center and the Director of the Third Department of Respiratory and Critical Care Medicine at China-Japan Friendship Hospital.
中日友好医院（中国综合实力前二十的公立医院之一）代华平教授，关于氢氧吸入改善肺纤维化的论文已发表[2]，该项研究显示，氢吸入通过抑制TGF-β1来减轻肺纤维化。
Professor Dai Huaping of China-Japan Friendship Hospital (one of the top 20 public hospitals in China in terms of overall strength) has published a paper on the improvement of pulmonary fibrosis through hydrogen-oxygen inhalation [2]. This study showed that hydrogen inhalation alleviates pulmonary fibrosis by inhibiting TGF-β1.
Asclepius Meditec Attracts Attention at the China Respiratory Medicine Development Conference
潓美氢氧医学，作为一种创新医学手段，在呼吸系统疾病的防治方面有着显著效果，受邀参加2026年中国呼吸学科发展大会，引起众多专家学者的关注。
Asclepius Meditec’s medical hydrogen-oxygen generator series, as an innovative medical approach, has shown remarkable effectiveness in the prevention and treatment of respiratory diseases. It was invited to participate in the 2026 China Respiratory Medicine Development Conference, attracting the attention of numerous experts and scholars.
潓美氢氧医学展位Asclepius Meditec Booth
潓美氢氧气机是全球唯一获批三类医疗器械的氢氧呼吸设备，2017年被中国国家药监局列入"国家创新"呼吸医疗设备，2020年被获批的第一张三类医疗器械证（国械注准20203080066）。2023年，获批第二张三类医疗器械证（国械注准20233081929）。
Asclepius Meditec's medical hydrogen-oxygen generator series is the only hydrogen-oxygen inhalation device globally approved as a Class III medical device. In 2017, it was listed as a "National Innovation" respiratory medical device by the China National Medical Products Administration (NMPA). In 2020, it received its first Class III medical device certificate (Registration Number: 20203080066). In 2023, it received its second Class III medical device certificate (Registration Number: 20233081929).
大会现场展示的潓美氢氧气机Asclepius Meditec's medical hydrogen-oxygen generators was displayed at the conference venue.
就在2025年11月份，国际氢医学与生物学学会（ISHMB）授予潓美医疗创办人林信湧先生“ISHMB产业创新突破奖”，以表彰潓美医疗取得氢氧气机「全球首创」医疗器械的开创性成就。
In November 2025, the International Society for Hydrogen Medicine and Biology (ISHMB) awarded Mr. Lin Hsin-Yung, founder of Asclepius Meditec, the "ISHMB Industrial Innovation Breakthrough Award" to recognize Asclepius Meditec’s pioneering achievement in developing the world's first medical hydrogen-oxygen generator.
“ISHMB产业创新突破奖”奖状"ISHMB Industry Innovation Breakthrough Award" Certificate
大会现场，潓美氢氧气机的体验区前人头攒动，众多专家学者与医护人员纷纷亲身体验。不少深耕呼吸领域的专家在体验后表示，潓美氢氧医学为呼吸系统疾病防治提供了新的思路与工具。
At the conference venue, the experience area for Asclepius Meditec's medical hydrogen-oxygen generators was bustling with people, and numerous experts, scholars, and medical professionals personally tried the product. Many experts specializing in respiratory medicine commented after their experience that Asclepius Meditec provides new ideas and tools for the prevention and treatment of respiratory diseases.
与会者们体验潓美氢氧气机Attendees experienced the Asclepius Meditec's medical hydrogen-oxygen generators
就在近期，由国家呼吸系统疾病临床医学研究中心牵头，潓美氢氧气机上市后四期临床研究表明，氢氧呼吸疗法，可以减少慢阻肺急性发作次数80%，潓美氢氧医学用实力赢得了行业认可。
Recently, a Phase IV clinical study led by the National Clinical Research Center for Respiratory Diseases showed that hydrogen-oxygen inhalation therapy can reduce the frequency of acute exacerbations of chronic obstructive pulmonary disease (COPD) by 80%. Asclepius Meditec has earned industry recognition through its proven effectiveness.
未来，随着氢氧医学研究的不断深入和临床应用的持续拓展，潓美医疗将继续携手呼吸领域同仁，以创新技术赋能呼吸健康事业，为完善感染性呼吸疾病照护体系、提升全民呼吸健康水平贡献更多力量，让前沿医学成果更好地惠及广大患者。
In the future, as research into hydrogen-oxygen medicine continues to deepen and its clinical applications expand, Asclepius Meditec will continue to collaborate with colleagues in the respiratory field, empowering respiratory healthcare with innovative technologies. We will contribute more to improving the care system for infectious respiratory diseases and enhancing the respiratory health of the entire population, ensuring that cutting-edge medical advancements better benefit a wider range of patients.
References：
